接受idarucizumab逆转达比加群抗凝治疗患者的医疗资源利用：RE-VERSE AD™研究的中期结果
RE-VERSE AD™研究中接受idarucizumab逆转达比加群抗凝治疗的患者的医疗资源利用数据，包含住院时长和ICU住院时长等指标。
基本信息
资源简介
接受idarucizumab逆转达比加群抗凝治疗患者的医疗资源利用：RE-VERSE AD™研究的中期结果
【一句话概览】
本数据集是 figshare 公开的结构化表格数据集，收录 3 个文件、合计 57.64 KB，主题涵盖 Healthcare resource utilization、idarucizumab、dabigatran etexilate、anticoagulation reversal、reversal agent，可用于统计建模、特征工程与队列分析，CC BY 4.0 许可开放获取。
【数据集背景】
本数据集源站标题为《Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study》。配套论文《Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study》发表于 Journal of Medical Economics（2017），DOI：10.1080/13696998.2016.1273229。源站首次发布：2017-01-17。
【数据内容】
源站原始描述：Aims: Patients treated with anticoagulants may experience serious bleeding or require urgent surgery or intervention, and may benefit from rapid anticoagulant reversal. This exploratory analysis assessed healthcare resource utilization (HCRU) in patients treated with idarucizumab, a specific reversal agent for dabigatran etexilate. Materials and methods: RE-VERSE AD™ (NCT02104947), a prospective, multi-center open-label study, is evaluating idarucizumab for dabigatran reversal in patients with s…
【数据结构与技术规格】
文件数 3 个，合计 57.64 KB。Supplementary Table 1a & 1b.docx：application/vnd.openxmlformats-officedocument.wordprocessingml.document，23.00 KB。Supplementary Table 2.docx：application/vnd.openxmlformats-officedocument.wordprocessingml.document，17.18 KB。Supplementary Table 3.docx：application/vnd.openxmlformats-officedocument.wordprocessingml.document，17.46 KB。数据集 DOI：10.6084/m9.figshare.4476206.v2。
【主题与分类】
源站学科分类：Space Science、Medicine、Cell Biology、Biotechnology、Developmental Biology、Marine Biology。主题标签：Healthcare resource utilization、idarucizumab、dabigatran etexilate、anticoagulation reversal、reversal agent。
【适用方向】
结构化表格数据可直接用于统计建模、特征工程与队列分析。
【获取与许可】
源站页面：https://tandf.figshare.com/articles/dataset/Healthcare_resource_utilization_in_patients_receiving_idarucizumab_for_reversal_of_dabigatran_anticoagulation_due_to_major_bleeding_urgent_surgery_or_procedural_interventions_interim_results_from_the_RE-VERSE_AD_sup_sup_study/4476206
使用许可：CC BY 4.0（https://creativecommons.org/licenses/by/4.0/）。
规范引用：Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study. Taylor & Francis. Pollack, Charles V.; Bernstein, Richard; Dubiel, Robert; Re…
【使用注意】
· 源站最后修改于 2023-06-02，引用时请注意版本时效。
下载信息
注册下载
需要注册 Kaggle 账号并登录后下载，适合需要跟踪下载记录和使用 API 的用户。
暂未开放公开下载
无需注册即可直接获取公开样本或文档，适合快速预览和评估数据集质量。
免登录有偿下载
公开数据集受托下载与技术交付服务。
提供高速下载与技术交付服务（收技术服务费，非数据销售）
暂未开放当前数据集主要来源为 Kaggle 公开托管，完整影像包建议通过原始链接或 Kaggle API 获取。
使用方式
数据集获取（Figshare）
- 源站标题：Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study
- DOI：10.6084/m9.figshare.4476206.v2
- 发布日期：2017-01-17
- 文件数：3 个
- 文件总体积：57.64 KB
- 源站页面：https://tandf.figshare.com/articles/dataset/Healthcare_resource_utilization_in_patients_receiving_idarucizumab_for_reversal_of_dabigatran_anticoagulation_due_to_major_bleeding_urgent_surgery_or_procedural_interventions_interim_results_from_the_RE-VERSE_AD_sup_sup_study/4476206
命令行下载
curl -L -o "Supplementary Table 1a & 1b.docx" "https://ndownloader.figshare.com/files/7206110"
curl -L -o "Supplementary Table 2.docx" "https://ndownloader.figshare.com/files/7206113"
curl -L -o "Supplementary Table 3.docx" "https://ndownloader.figshare.com/files/7206116"
文件清单
Supplementary Table 1a & 1b.docx（23.00 KB）Supplementary Table 2.docx（17.18 KB）Supplementary Table 3.docx（17.46 KB）
文件总体积 57.64 KB（源站 API 实测）。
数据说明
Aims: Patients treated with anticoagulants may experience serious bleeding or require urgent surgery or intervention, and may benefit from rapid anticoagulant reversal. This exploratory analysis assessed healthcare resource utilization (HCRU) in patients treated with idarucizumab, a specific reversal agent for dabigatran etexilate.
Materials and methods: RE-VERSE AD™ (NCT02104947), a prospective, multi-center open-label study, is evaluating idarucizumab for dabigatran reversal in patients with serious bleeding (Group A) or undergoing emergency surgery/procedures (Group B). HCRU outcome measures evaluated in the first 90 patients enrolled were use of blood products and pro-hemostatic agents, length of stay (LOS) in hospital, and LOS in intensive care unit (ICU).
Results: Blood products or pro-hemostatic agents were given to 63% (32/51) of patients in Group A and 23% (9/39) of patients in Group B on the day of/day after surgery. An overnight hospital stay was reported for 82% (42/51) of patients in Group A with median LOS = 7 (range = 1–71) bed-days. For Group B, 92% (36/39) had an overnight hospital stay with a median LOS = 9 (range = 1–92) bed-days. In Group A, 17 patients were admitted to the ICU for at least 1 day with median LOS = 4 (range = 1–44) days; in Group B the number was 15 with median LOS = 2 (range = 1–92) days.
Limitations: The lack of a control group and the small patient numbers limit the strength of the conclusions.
Conclusions: The use of idarucizumab may simplify emergency management of dabigatran-treated patients with life-threatening bleeds and reduce perioperative complications in patients undergoing emergency surgery.
许可
CC BY 4.0
引用
学术使用请引用 DOI 10.6084/m9.figshare.4476206.v2（source: https://tandf.figshare.com/articles/dataset/Healthcare_resource_utilization_in_patients_receiving_idarucizumab_for_reversal_of_dabigatran_anticoagulation_due_to_major_bleeding_urgent_surgery_or_procedural_interventions_interim_results_from_the_RE-VERSE_AD_sup_sup_study/4476206）。
数据缺失？
依托陕西、四川两大基地，我们与超过十家三甲医院建立直接合作关系，覆盖合规授权、采集治理、专业标注、数据交付的全流程，为AI医疗团队提供即拿即用的高质量临床数据。
⚡️ 需要数据支持或标注服务？立即联系我们获取专业方案。
